Redhill Biopharma Ltd (RDHL.OQ)
6.16USD
17 Aug 2018
$0.01 (+0.16%)
$6.15
$6.15
$6.30
$6.09
13,951
48,025
$11.47
$4.30
About
Overall
Financials
RedHill BioPharma has positive results from Crohn's disease trial
TEL AVIV Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.
RedHill BioPharma has positive results from Crohn's disease trial
TEL AVIV, July 30 Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.
BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share
* REDHILL BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial
* REDHILL BIOPHARMA ANNOUNCES LAST PATIENT ASSESSED FOR PRIMARY ENDPOINT IN RHB-104 PHASE III STUDY FOR CROHN’S DISEASE
BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia
* REDHILL BIOPHARMA ANNOUNCES ENROLLMENT OF 300TH PATIENT IN CONFIRMATORY PHASE III STUDY WITH TALICIA® FOR H. PYLORI INFECTION
BRIEF-Redhill Biopharma Plans To Meet With FDA In Q2 Of 2018 To Discuss Design For One, Two Pivotal Phase III Studies With Bekinda 12 Mg
* PLANS TO MEET WITH FDA IN Q2 OF 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:
BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda® 24 Mg For Acute Gastroenteritis
* REDHILL BIOPHARMA ANNOUNCES TWO ORAL PRESENTATIONS ON BEKINDA® 24 MG FOR ACUTE GASTROENTERITIS AT THE SAEM 2018 ANNUAL MEETING
BRIEF-Redhill Biopharma Q4 Basic Loss Per Ordinary Share $0.05
* CASH BALANCE AS OF DECEMBER 31, 2017 WAS $46.2 MILLION, A DECREASE OF $20 MILLION, COMPARED TO $66.2 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage:
Earnings vs. 
Estimates